FRANKFURT, July 25 German drugmaker Bayer
said a Phase III trial of cancer drug Nexavar in
patients with advanced breast cancer did not meet its primary
endpoint of delaying the progression of the disease.
The study, called Resilience, evaluated Nexavar in
combination with chemotherapeutic agent capecitabine, in women
with HER2-negative breast cancer.
Oral drug Nexavar, which Bayer is developing jointly with
Amgen, is approved for use against certain types of
liver, kidney and thyroid cancer.
Study details are expected to be presented at an upcoming
(Reporting by Ludwig Burger; Editing by Kirsti Knolle)